A drug developed 50 years ago and abandoned because it was considered to be too toxic has gained a second life in an international clinical trial. Research led by scientists at Dana-Farber Cancer Institute ...
May 13, 2015
First-in-class antibody mixture shows clinical activity against Tx-resistant, advanced colorectal cancer
Patients with advanced colorectal tumors without mutations in the RAS genes derive substantial benefit from anti-EGFR therapies; however, the disease eventually progresses, leaving these patients with few ...
May 11, 2015